Do We Have Your EAR Now?
In somewhat of a strange bedfellows situation, both PhRMA and GPhA support a proposed alternative to the FDA proposed labeling Rule called the “Expedited Agency Review” (EAR) for safety label changes.
Lachman Consultant Services Presents “Data Integrity: The Foundation of Metrics”
On Monday, April 20, 2015, the afternoon prior to the ISPE Quality Metrics Summit, Lachman Consultant Services will be presenting a training session on Data Integrity. The training session will be held in the Severn 1 meeting room of the Sheraton Inner Harbor Hotel in Baltimore (the same hotel as the ISPE Quality Metrics Summit), and will be followed by Q&A and a networking reception.
Lachman Consultant Services Presents “Data Integrity: The Foundation of Metrics”
On Monday, April 20, 2015, the afternoon prior to the ISPE Quality Metrics Summit, Lachman Consultant Services will be presenting a training session on Data Integrity. The training session will be held in the Severn 1 meeting room of the Sheraton Inner Harbor Hotel in Baltimore (the same hotel as the ISPE Quality Metrics Summit), and will be followed by Q&A and a networking reception.
Lachman Consultant Services Presents “Data Integrity: The Foundations of Metrics”
On Monday, April 20, 2015, the afternoon prior to the ISPE Quality Metrics Summit, Lachman Consultant Services will be presenting a forum on Data Integrity. The forum will be held in the BALLROOM NAME, the same hotel as the ISPE Quality Metrics Summit, and will be followed by Q&A and a networking and cocktail reception.
Proposed ANDA and 505(b)(2) Rule Provides Codification of Long-Time Agency Practices
There used to be two ways to trigger the 180-day market exclusivity provision for ANDA – a final court decision finding a patent not valid or not infringed or unenforceable and, of course, first commercial marketing of an ANDA product for which a PIV certification has been made after the 30-month stay….
More Guidance on the Way from Office of Generic Drugs, and Other Nuggets
At today’s’ Science and Regulatory Advisory Committee meeting at the GPhA Annual meeting in Orlando, Florida (apologies to those in the mid-West and Northeast), Keith Flanagan, the Office of Generic Drugs’ (OGD) Regulatory Counsel provided a look into some guidance documents the industry can expect to see in short order.
Trying Not to Compound the Problem – FDA Releases a Series of Guidance/ Policy Documents
Today, FDA released a set of 5 guidance documents designed to help compounders comply with new statutes, rules and regulations that can impact pharmacies, federal facilities, outsourcing facilities and physicians.
Proposed Rule to Save FDA Postage!
This is a first in a series of posts that will outline some of the more interesting and unique changes that the FDA is making in its Proposed Rule issued last week
Coach K Gets 1000 Wins and FDA Gets Califf from Duke
Dr. Robert Califf was appointed FDA Deputy Commissioner for Medical Products and Tobacco. As such, Dr. Califf will oversee the “Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health and the Center for Tobacco Products. He will also oversee the Office of Special Medical Programs in the Office of the Commissioner.”
Office of Pharmaceutical Quality Standing on Own Two Feet
Well, it’s January 2015 and the Office of Pharmaceutical Quality (OPQ) is about to be stood up (“FDA speak” for official) and will be addressing quality issues across the New Drugs and Generic Drugs arenas. The concept is of one quality voice and one standard, but more about this in a bit. The new leaders of OPQ are outlined in a CDER posting relative to the new organization.
